Zyxin (ZYX) promotes invasion and acts as a biomarker for aggressive phenotypes of human glioblastoma multiforme
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 100 (6) , 812-823
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- RETRACTED ARTICLE: STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cellsBMC Cancer, 2014
- Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional ResultsPLOS ONE, 2013
- Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK–p130Cas complexJournal of Cell Biology, 2012
- Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cellsMolecular Cancer, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Zyxin is involved in thrombin signaling via interaction with PAR‐1 receptorThe FASEB Journal, 2009
- Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell linesNucleic Acids Research, 2008
- Nitrosoureas Inhibit the Stathmin-Mediated Migration and Invasion of Malignant Glioma CellsCancer Research, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Tumour-cell invasion and migration: diversity and escape mechanismsNature Reviews Cancer, 2003